Janux Therapeutics, Inc.

Janux Therapeutics, Inc.

JANX·NASDAQ

$13.59

-1.4%
HealthcareBiotechnology

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

At a Glance

Live Snapshot
Market Cap$828.78M
EPS-1.8300
P/E Ratio-7.43
Earnings Date08/06/2026

No Dividend Yield Data

JANX has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

JANX has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

JANX has not reported any net dividends paid values in the available annual periods.

Janux Therapeutics, Inc.

Janux Therapeutics, Inc. Dividend History

JANX · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

JANX Dividend Payment History

JANX · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
janx

Janux Therapeutics, Inc. Payout Ratio Analysis

JANX · NASDAQ
Dividends Paid
0.00
2025
Net Income
-113.62M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.